Lilly and Boehringer roll toward EU approval with diabetes combo

Damian Garde Eli Lilly and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval ...

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Eric Palmer Eisai has gotten its second dose of good news in as many months. Weeks after getting an FDA approval for its thyroid cancer drug Lenvima, the struggling Japanese drugmaker ...

Cellectis pulls off a $228M IPO to bankroll its CAR-T ambitions

Damian Garde Cellectis, a French company with a proprietary spin on one of biotech's hottest fields, made an up-sized debut on Wall Street, grossing more than $ 228 million. FierceBiotech ...

Geriatrics experts call for halt to Low-T consumer ads

Tracy Staton A couple of geriatrics experts have joined the chorus of recommendations against testosterone therapy. But they're going a step further. They say drugmakers' enthusiastic ...

GlaxoSmithKline tags 180 sales-and-admin jobs for cutting in NC

Carly Helfand Last year, GlaxoSmithKline announced plans to slim down its Research Triangle Park, NC-based operations, chopping 900 jobs. Now, it's telling state officials that ...

Google’s Calico widens its R&D net with QB3 partnership

Damian Garde Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out ...

Allergy biotech hauls in $80M for its oral immunotherapy

Damian Garde Food allergy upstart Allergen Research Corporation raised an $ 80 million B round to get its lead candidate into late-stage development, pushing ahead with a treatment ...

Cost watchdogs back Novartis’ Xolair for big new market in chronic hives

Tracy Staton England's cost-effectiveness watchdogs have changed their mind on Xolair. The National Institute for Health and Care Excellence decided to back the Novartis asthma ...

Biogen Idec trims R&D staff, looks for new talent in chemistry, neurology

John Carroll Biogen Idec took a look at its R&D group and decided to trim out a small group of its research staffers on Thursday. A spokesperson for the company said today that ...

Colorado lawmakers pass biosim substitution bill

Tracy Staton Colorado's house of representatives passed a bill allowing pharmacists to substitute biosimilar versions of biotech drugs, even when the brands are prescribed by name. ...

Glaxo to reap $890M as it halves stake in South Africa’s Aspen

Carly Helfand Less than a year and a half ago, GlaxoSmithKline decided to sell off a chunk of its stake in fast-growing Aspen Pharmacare and reap the rewards from its investment. And ...

Third Rock’s faded Ember gets resuscitated in merger deal

Damian Garde Ember Therapeutics, a Third Rock Ventures-founded biotech startup that closed its doors late last year, is getting a second chance thanks to a small New York drug developer. FierceBiotech ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS